Skip to main content


Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: A comparison between angiotensin converting enzyme inhibitors and angiotensin receptor blockers on end stage renal disease and major adverse cardiovascular events in diabetic patients: a population-based dynamic cohort study in Taiwan

Fig. 3

End stage renal disease free rates stratified by chronic kidney disease or not for ACEi and ARB users after propensity score weighting. ACEi angiotensin converting enzyme inhibitors, ARB angiotensin receptor blockers, ESRD end stage renal disease, CKD chronic kidney disease

Back to article page